For decades, many novel ingredients entered supplements and functional foods through self-affirmed GRAS determinations — a company's own expert panel deciding safety, with no requirement to tell FDA. That pathway has let brands move fast on new botanicals, novel forms, and functional ingredients. A rule requiring mandatory FDA notification would close that shortcut, meaning safety data would need to hold up to federal review before an ingredient reaches market.
Whether FDA has the legal authority to make this change through rulemaking rather than legislation is genuinely contested, and expect challenges, delays, and possibly a narrower final rule than proposed. But brand owners shouldn't wait for that fight to resolve before acting.
If you're formulating around a self-affirmed ingredient, start building a real safety file now — toxicology data, intended use levels, exposure assumptions — the kind of documentation FDA notification would demand anyway. A manufacturing partner who already tracks ingredient regulatory status across categories can flag exposure before it becomes a launch delay or a compliance liability later.